{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:41:13Z","timestamp":1772804473659,"version":"3.50.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/ftd.0b013e31817fd4d4","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T14:54:56Z","timestamp":1236264896000},"page":"483-489","source":"Crossref","is-referenced-by-count":44,"title":["Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy"],"prefix":"10.1097","volume":"30","author":[{"given":"Nuria","family":"Rivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores Santos","family":"Buelga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian E","family":"Elger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Santos-Borbujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Dom\u00ednguez-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.1998.00769.x","article-title":"Therapeutic drug monitoring-antiepileptic drugs.","volume":"46","author":"Eadie","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R2-12-20210129","first-page":"CD002216","article-title":"Therapeutic monitoring of antiepileptic drugs for epilepsy.","volume":"1","author":"Tomson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1111\/j.1365-2125.2001.00394.x","article-title":"Therapeutic drug monitoring-antiepileptic drugs.","volume":"52","author":"Eadie","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs.","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":"Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.","volume":"29","author":"Jiao","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007691-199704000-00003","article-title":"Carbamazepine population pharmacokinetics in children: mixed-effect models.","volume":"19","author":"Delgado Iribarnegaray","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2003.00538.x","article-title":"Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.","volume":"29","author":"Bondareva","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.","volume":"20","author":"Blanco-Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children.","volume":"24","author":"Serrano","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","article-title":"Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.","volume":"37","author":"Yukawa","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00007691-199602000-00004","article-title":"The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed effects modeling.","volume":"18","author":"Banfield","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00194954","article-title":"Determination of phenobarbitone population clearance values for South African children.","volume":"48","author":"Botha","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00044011-199816020-00005","article-title":"Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy.","volume":"16","author":"Mullens","year":"1998","journal-title":"Clin Drug Invest"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","article-title":"Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures.","volume":"65","author":"Biton","year":"2005","journal-title":"Neurology"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00003495-199346010-00009","article-title":"Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs.","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 4","key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2005.463007.x","article-title":"An introduction to antiepileptic drugs.","volume":"46","author":"Perucca","year":"2005","journal-title":"Epilepsia"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1345\/aph.1A252","article-title":"Therapeutic drug monitoring of lamotrigine.","volume":"36","author":"Chong","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.","volume":"46","author":"Morris","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000066165","article-title":"Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures.","volume":"48","author":"Benetello","year":"2002","journal-title":"Eur Neurol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy.","volume":"39","author":"Grasela","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","article-title":"Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.","volume":"42","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine.","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.","volume":"50","author":"Chen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-4347(01)00044-5","article-title":"Macedo, et al. Lamotrigine analysis in biological fluids by high performance liquid chromatography (HPLC).","volume":"755","author":"Castel-Blanco","year":"2001","journal-title":"J Chromatography B Biomed Sci Appl"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","article-title":"Lamotrigine, a new aniconvulsant: pharmacokinetics in normal humans.","volume":"42","author":"Cohen","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics.","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 9","key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1528-1157.1999.tb02088.x","article-title":"The clinical pharmacoknetics of the new antiepileptic drugs.","volume":"40","author":"Perucca","year":"1999","journal-title":"Epilepsia"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose-an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM.","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01063558","article-title":"Evaluation of population (NONMEM) pharmacokinetic parameter estimates.","volume":"18","author":"Vozeh","year":"1990","journal-title":"J Pharmacokinet Biopharm"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine pharmacokinetics.","volume":"12","author":"Garnett","year":"1997","journal-title":"J Child Neurol"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drug and dosage implications.","volume":"21","author":"Armijo","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R37-12-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":"Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels.","volume":"4","author":"Froscher","year":"2002","journal-title":"Epileptic Disord"},{"key":"R38-12-20210129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1528-1157.1997.tb01111.x","article-title":"The concentration-effect relationship with lamotrigine (LTG).","volume":"38","author":"Gidal","year":"1997","journal-title":"Epilepsia"},{"key":"R39-12-20210129","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study.","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"R40-12-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200038030-00001","article-title":"Is there a role for therapeutic drug monitoring of new anticonvulsivants?.","volume":"38","author":"Perucca","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R41-12-20210129","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R42-12-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00228-006-0144-9","article-title":"Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.","volume":"62","author":"Almeida","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R43-12-20210129","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1007\/BF01371006","article-title":"Pharmacostatistical modeling for observational data.","volume":"19","author":"Grasela","year":"1991","journal-title":"J Pharmacokinet Biopharm"},{"key":"R44-12-20210129","first-page":"121","article-title":"Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers.","volume":"1","author":"Posner","year":"1991","journal-title":"J Pharm Med"},{"key":"R45-12-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.ftd.0000179854.16846.67","article-title":"The pharmacokinetics and interactions of new antiepileptic drugs: an overview.","volume":"27","author":"Bialer","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R46-12-20210129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance.","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"R47-12-20210129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00003088-199631040-00006","article-title":"Pharmacokinetic interactions of the new antiepileptic drugs.","volume":"31","author":"Rambeck","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R48-12-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00007691-199904000-00006","article-title":"Lamotrigine drug interactions in a TDM material.","volume":"21","author":"Bottiger","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R49-12-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","article-title":"Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.","volume":"55","author":"Kanner","year":"2000","journal-title":"Neurology"},{"key":"R50-12-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00007691-200210000-00009","article-title":"Does Lamotrigine influence valproate concentrations?","volume":"24","author":"Mataringa","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R51-12-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects.","volume":"60","author":"Anderson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R52-12-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31817fd4d4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:28:38Z","timestamp":1738978118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200808000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31817fd4d4","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}